These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17376931)

  • 1. Dysregulation of HER2/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells.
    Lin JH; Tsai CH; Chu JS; Chen JY; Takada K; Shew JY
    J Virol; 2007 Jun; 81(11):5705-13. PubMed ID: 17376931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Localization of Epstein-Barr virus to infiltrating lymphocytes in breast carcinomas and not malignant cells.
    Khan G; Philip PS; Al Ashari M; Houcinat Y; Daoud S
    Exp Mol Pathol; 2011 Aug; 91(1):466-70. PubMed ID: 21600202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
    Pan MH; Lin CC; Lin JK; Chen WJ
    J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.
    Okita R; Mougiakakos D; Ando T; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kiessling R
    J Immunol; 2012 Mar; 188(5):2136-45. PubMed ID: 22301547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer.
    Chakraborty AK; Liang K; DiGiovanna MP
    Cancer Res; 2008 Mar; 68(5):1538-45. PubMed ID: 18316619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and characterization of an in vivo model for Epstein-Barr virus positive gastric carcinoma.
    Oh ST; Cha JH; Shin DJ; Yoon SK; Lee SK
    J Med Virol; 2007 Sep; 79(9):1343-8. PubMed ID: 17607773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion.
    Ho CH; Chen CL; Li WY; Chen CJ
    Carcinogenesis; 2009 Aug; 30(8):1443-51. PubMed ID: 19483191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of Epstein-Barr virus from latency.
    Amon W; Farrell PJ
    Rev Med Virol; 2005; 15(3):149-56. PubMed ID: 15546128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia.
    Niller HH; Wolf H; Minarovits J
    Semin Cancer Biol; 2009 Jun; 19(3):158-64. PubMed ID: 19429479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus (EBV)-encoded RNA promotes growth of EBV-infected T cells through interleukin-9 induction.
    Yang L; Aozasa K; Oshimi K; Takada K
    Cancer Res; 2004 Aug; 64(15):5332-7. PubMed ID: 15289339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus (EBV) infection and gastric carcinoma: the approach through EBV infected epithelial cell lines.
    Sairenji T
    Jpn J Infect Dis; 1999 Jun; 52(3):110-2. PubMed ID: 10507989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
    Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
    Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus and breast cancer: state of the evidence for viral carcinogenesis.
    Glaser SL; Hsu JL; Gulley ML
    Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):688-97. PubMed ID: 15159298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporin A up-regulates and activates protein kinase C-zeta in EBV-infected and EBV-transformed human B-cells.
    Chen C; Johnston TD; Jeon H; Gedaly R; McHugh P; Ranjan D
    J Surg Res; 2009 May; 153(1):156-61. PubMed ID: 18486150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of HER2/HER3 co-receptor in breast carcinogenesis.
    Way TD; Lin JK
    Future Oncol; 2005 Dec; 1(6):841-9. PubMed ID: 16556064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival advantage of EBV-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2A.
    Hino R; Uozaki H; Inoue Y; Shintani Y; Ushiku T; Sakatani T; Takada K; Fukayama M
    Cancer Res; 2008 Mar; 68(5):1427-35. PubMed ID: 18316606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the RARRES1 gene in nasopharyngeal carcinoma.
    Kwok WK; Pang JC; Lo KW; Ng HK
    Cancer Genet Cytogenet; 2009 Oct; 194(1):58-64. PubMed ID: 19737656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Epstein-Barr Virus Infection on the Response of Human Breast Cancer Cells to Nicotine.
    Rajbongshi L; Noh MH; Kim YS; Hur DY
    Anticancer Res; 2021 Jul; 41(7):3449-3458. PubMed ID: 34230140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of latent membrane protein 2 isoforms in Epstein-Barr virus latency.
    Rechsteiner MP; Bernasconi M; Berger C; Nadal D
    Trends Microbiol; 2008 Nov; 16(11):520-7. PubMed ID: 18835714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.